Executive Committee


Executive Committee

Stéphane Bancel
Chief Executive Officer



Mr. Stéphane Bancel joined Moderna in the summer of 2011 when it was a one employee company. He has assembled a world-class team and raised nearly $2 billion between equity financing and upfront from licensing collaborations.

He was previously CEO of bioMérieux, a world leader in the diagnostics industry. bioMérieux had more than 6,000 employees, a market capitalization of €2.5 billion, and sales of more than €1.3 billion.

Prior to his time at bioMérieux, Mr. Bancel was the managing director of Eli Lilly Belgium and executive director of global manufacturing strategy and supply chain at Eli Lilly in Indianapolis, Indiana. He started at Lilly in their UK manufacturing plant outside London.

He holds a Master of Engineering from École Central Paris, a Master of Science in Chemical Engineering from the University of Minnesota and an MBA from Harvard Business School.

Mr. Bancel was named Ernst & Young 2017 New England Entrepreneur of the Year. He was ranked the number one CEO in the biotech sector according to the 2011 Thomson Reuters EXTEL Study. In 2009, he was elected a Young Global Leader by the World Economic Forum, and elected best CEO for investor relations in France.

Mr. Bancel serves as a supervisory director of Qiagen N.V. He also serves on the Board of Trustees for the Museum of Science, Boston.


Stephen Hoge, M.D.
President



As President of Moderna, Dr. Stephen Hoge leads drug discovery, preclinical development, and platform R&D, including chemistry, biology, formulation, and early stage technical development. Dr. Hoge joined Moderna in 2012, and as a leader from the earliest days of the company has had a wide range of responsibilities. These include heading corporate development and corporate strategy, and also founding  Moderna’s therapeutic area ventures in oncology, infectious disease, and rare diseases. 

Prior to Moderna, Dr. Hoge was a partner at McKinsey & Company and a leader in the firm’s healthcare practice. Prior to joining McKinsey, Dr. Hoge was a physician in New York. He holds an M.D. with thesis from the University of California, San Francisco and a B.S. in neuroscience from Amherst College.

Currently, Dr. Hoge also serves on the Board of Directors of Axcella, Inc., a clinical stage biotechnology company.


Juan Andres
Chief Technical Operations and Quality Officer



As Chief Technical Operations and Quality Officer, Juan Andres is responsible for the supply of product required for Moderna’s preclinical and clinical development programs, as well as scaling the CMC (chemistry, manufacturing and controls) processes across Moderna’s portfolio.  Juan also will lead all CMC late-stage development and future commercialization activities.

Mr. Andres was previously the Global Head of Technical Operations (Manufacturing and Supply Chain) for over 25,000 Novartis employees across all of its divisions. In this role, he had responsibility for all of Novartis’ manufacturing sites, and related support functions and technologies worldwide, overseeing small molecules drug substance and drug product, as well as biologics drug substance, drug product and technical development. Mr. Andres’ previous roles at Novartis included Group Novartis Quality Head, Global Head of Technical Research and Development, and Global Pharmaceutical Operations Head. Prior to Novartis, Mr. Andres worked at Eli Lilly & Co. for 18 years in a variety of manufacturing, production and quality roles in the United States, Puerto Rico, UK and Spain, most recently serving as Vice President, Pharmaceutical Manufacturing.

Mr. Andres holds a Master degree in Pharmacy from Alcala de Henares University in Madrid and completed an advanced development program at the London Business School.


Marcello Damiani
Chief Digital and Operational Excellence Officer



As Chief Digital and Operational Excellence Officer, Mr. Marcello Damiani brings a wealth of experience from both Tech companies and Life Science companies and a true passion for making Digital a reality. He has 20 years experience working in the IT field, with the last 10 years being spent in leadership roles for multinational companies in Europe and in the U.S.

Prior to joining Moderna, Mr. Damiani has been instrumental in conceiving and building creative IT solutions to help solve business challenges, first at Motorola and then at bioMérieux. His expertise is in visioning, strategizing and implementing innovative programs to update and streamline the digital landscapes. He is known for his ability to transform a company’s Information flow, and ultimately improving the product and the company’s processes through digitization.

Mr. Damiani possesses a Master of Science degree in Information Systems Architecture from the University of Toulouse in France, and he has just finished an international Executive MBA program through TRIUM, an alliance of three of the world’s top universities: the London School of Economics, New York University Stern Business School and the HEC School of Management in Paris.


Annie Seibold Drapeau
Chief Human Resources Officer



Ms. Annie Seibold Drapeau serves as Chief Human Resources Officer at Moderna, leading the company’s talent and organizational strategy. Prior to joining Moderna, Ms. Drapeau served as an Operating Partner at Bain Capital Private Equity, where she partnered with companies across the private equity portfolio on a range of talent and organizational capability initiatives.

Previously, Ms. Drapeau served as Executive Vice President, Strategy and Talent at Iron Mountain, a $3 billion data storage and protection business with nearly 20,000 employees worldwide. She had responsibility for corporate strategy, human resources and the company’s portfolio of emerging business opportunities. She also led the company’s diversity and sustainability efforts. Before joining Iron Mountain, Ms. Drapeau held leadership roles in human resources, strategy and finance at the Center for Leading Organizations, VistaPrint, Digitas, PepsiCo and JPMorgan.

Ms. Drapeau has been published in the Harvard Business Review on the topic of trust and leadership, and also led a session on that topic at the Annual Meeting of the World Economic Forum in Davos. Ms. Drapeau holds a bachelor’s in chemical engineering from Bucknell University and an MBA from the Amos Tuck School at Dartmouth College.

She chairs the Boston Advisory Board of Directors for the Posse Foundation, sits on the Alumni Association Board of Directors at Bucknell University and is a Trustee of the Nashoba Brooks School. 


Lori Henderson, J.D.
General Counsel and Corporate Secretary



As general counsel and corporate secretary, Ms. Henderson leads Moderna’s legal, governance and corporate compliance efforts. She comes to Moderna with nearly 30 years as a corporate attorney in both law firm and general counsel roles guiding both global public and private companies.

Ms. Henderson has deep business development, regulatory and governance experience, and has worked extensively with executive leadership teams both in public and private companies. She came to Moderna from Albany Molecular Research (AMRI), a Waltham-based pharmaceutical contract research and manufacturing organization, where she was Senior Vice President, General Counsel, Corporate Secretary and Head of Business Development. There she led global legal and business development functions, and had extensive involvement with pharmaceutical and licensing partners, the acquisition and integration of multiple companies, and ultimately the sale of the company to private equity in late 2017.

Prior to AMRI, she was General Counsel, Corporate Secretary and Chief Administrative Officer at Rand Worldwide, a technology sales and services organization and prior to that, General Counsel, Corporate Secretary and Chief Administrative Officer of Moldflow Corporation (which was sold to Autodesk). She started her career in the corporate practice of the Boston law firm Goodwin Procter.

Ms. Henderson received her Juris Doctorate from The George Washington University Law School and her B.A. from Gordon College.


Lorence Kim, M.D.
Chief Financial Officer



Dr. Lorence Kim joined Moderna from Goldman Sachs where he was a managing director and co-head of the U.S. biotechnology investment banking ef fort. He joined Goldman Sachs in 1999 as a summer associate and was named managing director in 2008. As a member of the healthcare investment banking group for nearly 14 years, Dr. Kim’s responsibilities included corporate finance and mergers and acqu isitions (M&A) for the pharmaceutical and biotechnology industries, with several billi on in equity and equity linked financings, and more than $55 billion in M&A transactions.

Prior to joining Goldman Sachs, Dr. Kim worked in various medical research and consulting positions concurrent with his graduate studies. Dr. Kim graduated from Harvard University, magna cum laude and Phi Beta Kappa with an A.B. in biochemical sciences in 1995. He also earned an MBA in healthcare management as a Palmer Scholar from the Wharton School of the University of Pennsylvania in 2000 and an M.D. from the University of Pennsylvania’s School of Medicine in 2000.

Dr. Kim is currently a member of the Board of Directors of Seres Therapeutics.


John Mendlein, Ph.D.
President, Corporate and Product Strategy



As President, Corporate and Product Strategy, Dr. Mendlein is responsible for corporate strategy, product advancement and strategy, partnering and product protection. He was previously a member of Moderna’s Board of Directors.

Dr. Mendlein has helped start and lead numerous innovative life sciences companies. He was previously Executive Chairman and CEO of aTyr Pharma, CEO of Adnexus Therapeutics, Inc., (acquired by BMS), and currently serves as vice chairman of the board of Fate Therapeutics. He was also Chairman and Chief Executive Officer of Affinium Pharmaceuticals, Ltd. (acquired by Debiopharm Group), and board member, General Counsel and Chief Knowledge Officer at Aurora Bioscience Corporation (acquired by Vertex Pharmaceuticals). He also formerly served on the boards of the Biotechnology Innovation Organization (BIO), Editas Medicine, Inc., Monogram Biosciences (a subsidiary of LabCorp), and Axcella Health, Inc.

Dr. Mendlein holds a Ph.D. in physiology and biophysics from the University of California, Los Angeles, a J.D. from the University of California, Hastings College of the Law, and a B.S. in biology from the University of Miami. Dr. Mendlein is the co-author or co-inventor of over 210 publications and published patents. He is a founder and board member of Homes for Sudan, a non-profit in Boston, and a scientific advisory board member for Ocean Discovery Institute, a non-profit in San Diego.


Megan Pace
Chief Corporate Affairs Officer



As chief corporate affairs officer, Ms. Pace is responsible for Moderna’s communications and public affairs activities, including corporate and internal communications, government affairs, community relations and patient advocacy. She joins Moderna after nearly 20 years working with and for leading biotechnology and pharmaceutical companies.

Prior to Moderna, Ms. Pace was senior vice president, strategic operations and PKR program executive at Agios, where she served as a member of the executive team. She was also the senior vice president of corporate communications at Vertex, during the period when the company evolved from a research and development organization and successfully launched its first two commercial products. In this role, she was on the company’s leadership team and was responsible for global corporate, product and employee communications and patient advocacy. Ms. Pace was also senior director, Public Affairs at Genentech, Inc. where she was responsible for product communications and public affairs. She also worked on the communications and government affairs teams at Eli Lilly and Company as well as at Porter Novelli, a global public relations firm. She began her career working on political campaigns in her home state of Florida and in a Congressional office in Washington DC.

Ms. Pace holds a B.A. from the College of Charleston. She is a board member of the Boomer Esiason Foundation and the Make-a-Wish Foundation of Massachusetts and Rhode Island.

 


Tal Zaks, M.D., Ph.D.
Chief Medical Officer



As Chief Medical Officer, Dr. Tal Zaks oversees clinical development and regulatory affairs across Moderna. Prior to joining Moderna, Dr. Zaks was senior vice president and head of Global Oncology at Sanofi, where he was responsible for all a spects of oncology drug discovery, development and commercialization.

Dr. Zaks began his industry career at GlaxoSmithKline in the genetics research group, where he built the oncology translational medicine team and led translational research on lapatinib as well as the in-licensing and clinical development of foretinib. In addition to his industry work, Dr. Zaks is associate professor of medicine at the University of Pennsylvania, and has served as a volunteer physician at the Philadelphia Veterans Administration Medical Center, treating patients with genitourinary cancers.

Dr. Zaks received his M.D. and Ph.D. from the Ben Gurion University in Israel and conducted post-doctoral research at the U.S. National Institutes of Health. He completed his clinical training in internal medicine at Temple University Hospital followed by a fellowship in medical oncology at the University of Pennsylvania.

Dr. Zaks serves on the Board of Directors of Adaptimmune Therapeutics plc.